Insmed Incorporated Annual Revenue, Number of Employees, Growth and Funding
Estimated Revenue & Financials
- Insmed Incorporated's estimated annual revenue is currently $66.3M per year.
- Insmed Incorporated received $437.3M in venture funding in January 2018.
- Insmed Incorporated's estimated revenue per employee is $144,847
- Insmed Incorporated has 458 Employees.
- Insmed Incorporated grew their employee count by 10% last year.
- Insmed Incorporated currently has 12 job openings.
|Renu Gupta||Executive VP Development & CMO|
|Christine Pellizzari||Chief Legal Officer|
|Nicole Merlo||Associate Director|
|Sharon Haines||Regional Director, Medical Affiars, MSLs East|
|Gina Eagle||Vice President, Clinical Development at Insmed, Inc.|
|Kevin McDermott||Vice President, Global Market Access|
|Sarah Canberg||Director, Corporate Counsel|
|Fernandez Carlos||Sr Medical Director|
|Janine Del Vecchio||Associate Director Data Management|
|Jennifer English||Senior Director, Market Access, Pricing and Gross-to-Net Financial Operations (FP&A)|
What Is Insmed Incorporated?
Insmed is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. The Company is dedicated to developing and bringing to market therapies that make a real difference in patients lives, while striving to understand and enhance the entire patient experience, from diagnosis and treatment to everyday living. Headquartered in Bridgewater, NJ, we are a rapidly growing company with offices in seven countries.keywords:Biotechnology,Healthcare,Pharmaceuticals
Number of Employees
Employee Growth %
|Name||Revenue||Number of Employees||Employee Growth||Total Funding|
|L Oreal USA||N/A||0||N/A||N/A|
|Legend Biotech ...||$17.7M||122||149%||N/A|
Insmed Incorporated News
On Wednesday, shares of Insmed Incorporated (NASDAQ:INSM) marked $19.21 per share versus a previous $18.20 closing price. With having ...
Insmed Incorporated [NASDAQ: INSM] dipped by -2.03% on the last trading session, reaching $18.82 price per share at the time. Insmed ...
Insmed Incorporated (NASDAQ:INSM)went down by -1.04% from its latest closing price when compared to the 1-year high value of $33.13 and ...
Insmed Incorporated Funding
|2003-07-14||$12.0M||Private Placement||Wells Fargo Securities||Article|
|2007-05-07||$18.2M||Undisclosed||CE Unterberg Towbin||Article|
|2013-07-18||$62.4M||Undisclosed||Leerink Swann LLC||Article|
|2017-09-08||$402.5M||Undisclosed||Goldman Sachs & Co. LLC||Article|
|2018-01-24||$300.0M||Undisclosed||Goldman Sachs & Co. LLC||Article|
|2018-01-25||$437.3M||Undisclosed||Goldman Sachs & Co. LLC||Article|
Insmed Incorporated Executive Hires
|2002-01-04||Frederick Dunn||VP Clinical Development||Article|
|2002-08-20||Lewis Stuart||VP Commercial Dev||Article|
|2002-09-10||Mary Callan||VP Corporate Development||Article|
|2003-06-20||Ronald D. Gunn||EVP||Article|
|2008-07-29||Jim Miller||VP Process Development||Article|
|2010-03-23||Nicholas A. LaBella||Chief Scientific Officer||Article|
|2012-05-17||Donald J. Hayden||Chairman||Article|
|2012-11-08||Andrew Drechsler||Chief Financial Officer||Article|
|2013-04-02||Matthew Pauls||Chief Commercial Officer||Article|
|2013-07-30||Christine A. Pellizzari||General Counsel/Corporate Secretary||Article|
|2015-03-24||Eugene Sullivan||Chief Medical/Scientific Officer||Article|
|2016-09-28||Roger Adsett||Chief Commercial Officer||Article|
|2019-03-28||John Goll||Chief Accounting Officer||Article|
Insmed Incorporated Acquisitions